Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resistant depression Phase 2 trials Training programme to be conducted in partnership with industry-leading educational company, FluenceInitiation of training represents key step to incorporate psychedelic-assisted psyc.
COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
COMPASS Pathways announces publication in of paper on therapist training programme for psilocybin therapy Formal and scalable methodology for psychological support in psilocybin therapy London, UK 3 February 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has shared details of its comprehensive and rigorous therapist … COMPASS Pathways announces publication in Frontiers in Psychiatry Formal and scalable methodology for psychological support in psilocybin therapy
London, UK 3 February 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has shared details of its comprehensive and rigorous therapist training programme for psilocyb
Compass Pathways: COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
Frontiers in Psychiatry
Formal and scalable methodology for psychological support in psilocybin therapy
London, UK - 3 February 2021 COMPASS Pathways plc today. The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy. It is currently being used to train therapists taking part in COMPASS s phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, as approved by the US Food and Drug Administration (FDA), as part of COMPASS s Investigational New Drug (IND) application.
In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists. COMPASS developed the therapist training programme alongside leading experts in mental health and psychedelic research, inclu